We serve Chemical Name:3,5-Dinitroaniline CAS:618-87-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3,5-Dinitroaniline
CAS.NO:618-87-1
Synonyms:3,5-dinitroaniline;EINECS 210-567-8;MFCD00007263
Molecular Formula:C6H5N3O4
Molecular Weight:183.12200
HS Code:2921420090
Physical and Chemical Properties:
Melting point:160-162 °C(lit.)
Boiling point:397.9ºC at 760 mmHg
Density:1.586 g/cm3
Index of Refraction:1.679
PSA:117.66000
Exact Mass:183.02800
LogP:2.71280
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1596 6.1/PG 2
Packing Group:II
Contact us for information like 3,5-dinitroaniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00007263 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,5-dinitroaniline Use and application,MFCD00007263 technical grade,usp/ep/jp grade.
Related News: EMA said the drug can help improve the respiratory function of Pompe disease patients, and the most common side effects include hypersensitivity (including anaphylaxis) and infusion-associated reactions. N-(4-chlorobenzyl)-4-(2-methoxyphenyl)-5-(methylthio)thiazol-2-amine manufacturers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit (6aR,7S)-7-(p-tolyl)-6a,7-dihydro-6H-benzo[b]thiochromeno[4,3-e][1,4]thiazepine suppliers The new R&D People and Culture Strategy aims to make UK the most ideal place for research and innovation, led by individuals, universities and businesses, and funders. 2,6-Diazabicyclo[2.2.2]octane-3,5-dione, 1-ethyl-4-(2-methylpropyl)- vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit (6aR,7S)-7-(p-tolyl)-6a,7-dihydro-6H-benzo[b]thiochromeno[4,3-e][1,4]thiazepine suppliers The new R&D People and Culture Strategy aims to make UK the most ideal place for research and innovation, led by individuals, universities and businesses, and funders. 2,6-Diazabicyclo[2.2.2]octane-3,5-dione, 1-ethyl-4-(2-methylpropyl)- vendor & factory.
